FR3109723A1 - Composition for strengthening and / or regulating the immune response - Google Patents
Composition for strengthening and / or regulating the immune response Download PDFInfo
- Publication number
- FR3109723A1 FR3109723A1 FR2004394A FR2004394A FR3109723A1 FR 3109723 A1 FR3109723 A1 FR 3109723A1 FR 2004394 A FR2004394 A FR 2004394A FR 2004394 A FR2004394 A FR 2004394A FR 3109723 A1 FR3109723 A1 FR 3109723A1
- Authority
- FR
- France
- Prior art keywords
- composition
- composition according
- proportion
- total weight
- weight relative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 230000028993 immune response Effects 0.000 title claims abstract description 20
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 14
- 238000005728 strengthening Methods 0.000 title abstract description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 19
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims abstract description 18
- 235000005875 quercetin Nutrition 0.000 claims abstract description 10
- 229960001285 quercetin Drugs 0.000 claims abstract description 10
- 235000001258 Cinchona calisaya Nutrition 0.000 claims abstract description 9
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 9
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 9
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims abstract description 9
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000948 quinine Drugs 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 230000002708 enhancing effect Effects 0.000 claims abstract description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 8
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 7
- 230000003449 preventive effect Effects 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- 235000012754 curcumin Nutrition 0.000 claims description 4
- 229940109262 curcumin Drugs 0.000 claims description 4
- 239000004148 curcumin Substances 0.000 claims description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 235000011477 liquorice Nutrition 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 235000002414 D-alpha-tocopherylacetate Nutrition 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- 239000011740 D-alpha-tocopherylacetate Substances 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- 229940039770 d-alpha-tocopheryl acetate Drugs 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 description 29
- 108090000695 Cytokines Proteins 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000035939 shock Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 8
- 241000157855 Cinchona Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 235000021516 Cinchona officinalis Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229930186743 Quercetol Natural products 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composition de renforcement et/ou de régulation de la réponse immunitaire La présente invention porte sur une composition de renforcement et/ou de régulation de la réponse immunitaire chez un mammifère, en particulier chez un être humain, comprenant de la quercétine et de la quinine. Composition for strengthening and/or regulating the immune response The present invention relates to a composition for enhancing and/or regulating the immune response in a mammal, in particular in a human, comprising quercetin and quinine.
Description
La présente invention porte sur une composition de renforcement et/ou de régulation de la réponse immunitaire chez un mammifère, en particulier chez un être humain.The present invention relates to a composition for enhancing and/or regulating the immune response in a mammal, in particular in a human.
En particulier, la présente invention porte sur une composition immunomodulatrice ou régulatrice de la réponse immunitaire, c’est-à-dire sur une composition permettant de moduler l'équilibre des cytokines au sein d’un organisme, en particulier au sein de l’organisme d’un mammifère et plus particulièrement chez l’être humain.In particular, the present invention relates to an immunomodulating or regulating composition of the immune response, that is to say a composition making it possible to modulate the balance of cytokines within an organism, in particular within the organism of a mammal and more particularly in the human being.
La présente invention porte également sur de telles compositions pour utilisation dans le traitement, en particulier dans le traitement préventif, de maladies et/ou de pathologies virales et/ou bactériennes.The present invention also relates to such compositions for use in the treatment, in particular in the preventive treatment, of viral and/or bacterial diseases and/or pathologies.
De manière générale, lors d’une infection, c’est-à-dire lors d’une invasion de l' organisme d’un individu par un agent étranger (comme une bactérie ou un virus) provoquant un état pathologique par lésion des cellules locales, libération de substances toxiques ou encore par réaction intracellulaire germe-anticorps, des molécules libérées par le système immunitaire visent à détruire cet agent étranger.In general, during an infection, that is to say during an invasion of the organism of an individual by a foreign agent (such as a bacterium or a virus) causing a pathological state by lesion of the cells local, release of toxic substances or even by intracellular germ-antibody reaction, molecules released by the immune system aim to destroy this foreign agent.
La première phase de toute réaction immunitaire est celle de la reconnaissance et de la présentation au système immunitaire des antigènes des agents étrangers (virus, bactéries, …), ce dont se chargent les cellules présentatrices d'antigènes. Par la suite, il y a amplification de la réaction de défense : les lymphocytes t auxiliaires attirent les différents acteurs de la défense immunitaire à l'endroit où l'agent pathogène a été localisé. Après la phase de reconnaissance et celle d'amplification, la troisième phase est celle de l'élimination de l’agent étranger. Plusieurs « acteurs » ou molécules interviennent, notamment les lymphocytes b et les lymphocytes t cytotoxiques. Les lymphocytes b produisent des anticorps qui se lient aux antigènes étrangers et empêchent les agents étrangers de se fixer sur de nouvelles cellules et de les infecter tandis que les lymphocytes t cytotoxiques libèrent des enzymes destructrices ou encore des macrophages qui éliminent les cellules infectées. Les réactions des différents « acteurs » sont coordonnées, les cellules échangeant des signaux de régulation, soit par contacts intercellulaires directs, soit par des médiateurs solubles, libérés par les cellules dans le milieu environnant que ce sont les cytokines.The first phase of any immune reaction is that of the recognition and presentation to the immune system of the antigens of foreign agents (viruses, bacteria, etc.), which the antigen-presenting cells take care of. Thereafter, there is amplification of the defense reaction: the helper T lymphocytes attract the various actors of the immune defense to the place where the pathogenic agent has been located. After the recognition phase and the amplification phase, the third phase is that of the elimination of the foreign agent. Several "actors" or molecules are involved, in particular the B lymphocytes and the cytotoxic T lymphocytes. B lymphocytes produce antibodies that bind to foreign antigens and prevent foreign agents from attaching to new cells and infecting them, while cytotoxic T lymphocytes release destructive enzymes or macrophages that eliminate infected cells. The reactions of the various "actors" are coordinated, the cells exchanging regulatory signals, either by direct intercellular contact, or by soluble mediators, released by the cells in the surrounding environment, such as cytokines.
En ce sens, les cytokines sont des agents essentiels du système immunitaire et jouent le rôle de signaux permettant aux cellules d'agir à distance sur d'autres cellules pour en réguler l'activité et la fonction. Parmi les cytokines, on distingue (1) les interférons dont la principale action est l'inhibition de la réplication virale dans des cellules infectées ; (2) les interleukines qui assurent les échanges d'informations entre les globules blancs ; (3) les facteurs de croissance hématopoiétiques qui stimulent la production de cellules du système sanguin ; (4) les facteurs de croissance qui contrôlent la formation et l'entretien du tissu conjonctif et (5) les chimiokines qui participent aux phénomènes de migration des leucocytes.In this sense, cytokines are essential agents of the immune system and play the role of signals allowing cells to act remotely on other cells to regulate their activity and function. Among the cytokines, there are (1) interferons whose main action is the inhibition of viral replication in infected cells; (2) interleukins which ensure the exchange of information between white blood cells; (3) hematopoietic growth factors which stimulate the production of blood system cells; (4) growth factors which control the formation and maintenance of connective tissue and (5) chemokines which participate in leukocyte migration phenomena.
Les cellules immunitaires au repos ne produisent généralement pas de cytokines. Elles n'en produisent qu'après avoir été activées, en général par un agent pathogène ou agent étranger (comme une bactérie ou un virus). Lors d'une réaction immunitaire, seules quelques cellules immunitaires produisent, localement, des cytokines. Cela limite la réaction immunitaire dans le temps et dans l'espace, l'efficacité étant alors optimisée et les effets délétères pour l'organisme minimisés. En effet, les cytokines doivent être efficaces localement et rester concentrées sur le site de l'inflammation. A cette fin, elles sont contrôlées par d'autres cytokines qui ont un rôle global et modulent les équilibres immunitaires et inflammatoires des réactions en cours.Resting immune cells generally do not produce cytokines. They only produce it after being activated, usually by a pathogenic agent or foreign agent (such as a bacterium or a virus). During an immune reaction, only a few immune cells locally produce cytokines. This limits the immune reaction in time and space, the efficiency then being optimized and the deleterious effects for the organism minimized. Indeed, cytokines must be effective locally and remain concentrated at the site of inflammation. To this end, they are controlled by other cytokines which have a global role and modulate the immune and inflammatory balances of the reactions in progress.
Il est évident que les réactions inflammatoires, c'est-à-dire l'accumulation des cytokines qui activent le système immunitaire, sont indispensables aux réactions de défense, puisqu'elles attirent, sur le site agressé, les « acteurs » nécessaires à la mise en œuvre d’une défense immunitaire aussi efficace que possible. Cependant, lorsque la réaction de défense mise en place par le système immunitaire est disproportionnée et que les cytokines sont trop abondantes, elles peuvent créer des lésions et entrainer des séquelles, telles des nécroses locales, voire globales : on parle alors d’orage ou de choc cytokinique. Notons que ceci est particulièrement le cas pour des cytokines inflammatoires telles que l'interleukine 1 et le tnf alpha.It is obvious that the inflammatory reactions, that is to say the accumulation of cytokines which activate the immune system, are essential to the defense reactions, since they attract, on the attacked site, the "actors" necessary for the implementation of an immune defense as effective as possible. However, when the defense reaction put in place by the immune system is disproportionate and the cytokines are too abundant, they can create lesions and lead to sequelae, such as local or even global necrosis: we then speak of a storm or cytokine shock. Note that this is particularly the case for inflammatory cytokines such as interleukin 1 and tnf alpha.
Le choc cytokinique ou orage cytokinique est la forme la plus grave du syndrome de libération des cytokines (SLC) et correspond donc à une production excessive de cytokines déclenchée par un agent pathogène ou agent étranger. Classiquement, le choc cytokinique se manifeste par une violente réponse inflammatoire du système immunitaire. Il s’agit d’une réponse inadaptée, nocive et généralement mortelle si un traitement approprié n’est pas rapidement appliqué. Le choc cytokinique survient quand un grand nombre de globules blancs (de type cellule B, cellule T, cellule tueuse naturelle, macrophage, cellule dendritique et monocyte) est activé et libère des cytokines inflammatoires qui, à leur tour, activent encore plus de globules blancs. Pour ces raisons, la régulation de la réponse immunitaire (ou immunomodulation) et par conséquent la régulation de la libération des cytokines sont essentielles afin de moduler l'équilibre des cytokines au sein d’un organisme.Cytokine shock or cytokine storm is the most severe form of cytokine release syndrome (CLS) and therefore corresponds to excessive production of cytokines triggered by a pathogen or foreign agent. Classically, cytokine shock is manifested by a violent inflammatory response of the immune system. It is a maladaptive, harmful, and usually fatal response if proper treatment is not promptly applied. Cytokine shock occurs when a large number of white blood cells (B cell, T cell, natural killer cell, macrophage, dendritic cell and monocyte type) are activated and release inflammatory cytokines which in turn activate even more white blood cells . For these reasons, the regulation of the immune response (or immunomodulation) and therefore the regulation of cytokine release are essential in order to modulate the balance of cytokines within an organism.
De nos jours, il existe des compositions de renforcement et/ou de régulation de la réponse immunitaire comprenant des substances actives naturelles et/ou synthétiques pour moduler l'équilibre des cytokines au sein d’un organisme (on parle généralement de compositions immunomodulatrices). Toutefois, malheureusement, il s’avère que les compositions actuelles ne sont pas suffisamment efficaces et qu’elles ne permettent pas d’empêcher qu’une réponse immunitaire trop forte et disproportionnée se mettent en place face à un agent étranger, en particulier face à un nouvel agent étranger, c’est-à-dire face à un agent étranger auquel l’organisme n’a pas encore jamais été confronté.Nowadays, there are compositions for strengthening and/or regulating the immune response comprising natural and/or synthetic active substances to modulate the balance of cytokines within an organism (we generally speak of immunomodulatory compositions). However, unfortunately, it turns out that the current compositions are not sufficiently effective and that they do not make it possible to prevent an excessively strong and disproportionate immune response from being set up against a foreign agent, in particular against a new foreign agent, that is to say facing a foreign agent with which the organism has never yet been confronted.
Concrètement, les compositions actuelles de renforcement et/ou de régulation de la réponse immunitaire ne parviennent pas systématiquement à empêcher une présence trop abondante et excessive de cytokines en réponse à la présence d’un agent étranger. En d’autres termes, les compositions actuelles de renforcement et/ou de régulation de la réponse immunitaire ne parviennent pas systématiquement à empêcher l’apparition d’un choc cytokinique, ceci en particulier lorsque l’organisme est confronté à un nouvel agent étranger.In concrete terms, current compositions for strengthening and/or regulating the immune response do not systematically succeed in preventing an excessively abundant and excessive presence of cytokines in response to the presence of a foreign agent. In other words, the current compositions for strengthening and/or regulating the immune response do not systematically succeed in preventing the appearance of a cytokine shock, this in particular when the organism is confronted with a new foreign agent.
A ce jour, il existe donc un réel besoin de procurer une composition de renforcement et/ou de régulation de la réponse immunitaire qui permette d’éviter une libération excessive et potentiellement dangereuse de cytokines dans l’organisme, c’est-à-dire une composition de renforcement et/ou de régulation de la réponse immunitaire qui permette d’éviter l’apparition d’un choc cytokinique.To date, there is therefore a real need to provide a composition for strengthening and/or regulating the immune response which makes it possible to avoid an excessive and potentially dangerous release of cytokines in the body, that is to say a composition for strengthening and/or regulating the immune response which makes it possible to prevent the appearance of a cytokine shock.
Pour adresser au moins en partie ces problèmes, il est prévu, suivant l’invention, une composition de renforcement et/ou de régulation de la réponse immunitaire chez un mammifère, en particulier chez un être humain, comprenant de la quercétine et de la quinine.To at least partially address these problems, provision is made, according to the invention, for a composition for strengthening and/or regulating the immune response in a mammal, in particular in a human being, comprising quercetin and quinine .
La quercétine ou le quercétol est un composé organique de la famille des flavonoïdes, plus précisément du sous-groupe des flavonols. Il s’agit d’un métabolite secondaire présent dans certaines plantes. La quinine est un alcaloïde naturel antipyrétique analgésique.Quercetin or quercetol is an organic compound from the flavonoid family, more specifically from the flavonol subgroup. It is a secondary metabolite found in some plants. Quinine is a natural antipyretic analgesic alkaloid.
Selon l’invention ladite quercétine et/ou ladite quinine est naturelle ou synthétique.According to the invention, said quercetin and/or said quinine is natural or synthetic.
Dans le cadre de la présente invention, il a été mis en évidence qu’une telle composition est efficace pour renforcer et/ou réguler la réponse immunitaire et ainsi éviter l’apparition d’un choc cytokinique, ceci grâce à l’effet synergique inattendu observé entre la quercétine et la quinine.In the context of the present invention, it has been demonstrated that such a composition is effective in strengthening and/or regulating the immune response and thus avoiding the appearance of a cytokine shock, this thanks to the unexpected synergistic effect observed between quercetin and quinine.
Plus particulièrement, par exemple lorsque l’agent étranger ou pathogène est un virus, il a été montré qu’une composition selon l’invention permet d’une part de réduire significativement la charge virale par réduction de l’accrochage du virus (ARN) au niveau cellulaire, par réduction de l’intégration du patrimoine génétique du virus au sein du système de réplication cellulaire et par réduction du volume de réplication. D’autre part, il a été montré qu’une composition selon l’invention permet de réguler et de moduler la réponse immunitaire (immunomodulation) face au virus et par conséquent de réguler la libération des cytokines, ceci permettant d’éviter toute réponse disproportionnée du système immunitaire et tout risque de mise en place d’un choc cytokynique.More particularly, for example when the foreign agent or pathogen is a virus, it has been shown that a composition according to the invention makes it possible, on the one hand, to significantly reduce the viral load by reducing the attachment of the virus (RNA) at the cellular level, by reducing the integration of the genetic heritage of the virus within the cellular replication system and by reducing the volume of replication. On the other hand, it has been shown that a composition according to the invention makes it possible to regulate and modulate the immune response (immunomodulation) against the virus and consequently to regulate the release of cytokines, this making it possible to avoid any disproportionate response. of the immune system and any risk of developing cytokine shock.
Une composition selon l’invention est particulièrement adéquate pour assurer un traitement de fond préventif chez un individu de telle sorte à renforcer, à « préparer » et/ou à réguler la réponse immunitaire de ce dernier. Concrètement, avec une composition selon l’invention, l’immunomodulation (régulation de la réponse immunitaire) est renforcée afin que la réponse immunitaire soit adéquate et optimale en réponse à la présence d’un agent étranger ou pathogène, ceci même lorsque ce dernier est inconnu du système immunitaire de l’individu. Ceci est particulièrement avantageux puisqu’il est généralement bien trop tard pour agir une fois un choc cytokynique en place.A composition according to the invention is particularly suitable for ensuring a preventive preventive treatment in an individual so as to reinforce, to “prepare” and/or to regulate the immune response of the latter. Concretely, with a composition according to the invention, the immunomodulation (regulation of the immune response) is reinforced so that the immune response is adequate and optimal in response to the presence of a foreign or pathogenic agent, this even when the latter is unknown to the individual's immune system. This is particularly advantageous since it is usually much too late to act once a cytokine shock is in place.
Avantageusement, pour une composition selon l’invention, ladite quercétine est présente à raison de 15% à 80% en poids par rapport au poids total de la composition, de préférence à raison de 25% à 50% en poids par rapport au poids total de la composition.Advantageously, for a composition according to the invention, said quercetin is present in a proportion of 15% to 80% by weight relative to the total weight of the composition, preferably in a proportion of 25% to 50% by weight relative to the total weight of composition.
De préférence, pour une composition selon l’invention, ladite quinine est présente à raison de 15% à 60% en poids par rapport au poids total de la composition, de préférence à raison de 25% à 50% en poids par rapport au poids total de la composition.Preferably, for a composition according to the invention, said quinine is present in a proportion of 15% to 60% by weight relative to the total weight of the composition, preferably in a proportion of 25% to 50% by weight relative to the weight composition total.
De telles quantités en poids de quercétine et de quinine ont été déterminées comme étant adéquates afin que la composition selon l’invention renforce, « prépare » et/ou régule la réponse immunitaire d’un individu et afin que la composition selon l’invention permette d’éviter tout choc cytokynique.Such quantities by weight of quercetin and quinine have been determined as being adequate so that the composition according to the invention reinforces, "prepares" and/or regulates the immune response of an individual and so that the composition according to the invention allows to avoid any cytokine shock.
Préférentiellement, une composition selon l’invention comprend en outre de la réglisse.Preferably, a composition according to the invention also comprises liquorice.
Avantageusement, selon l’invention, ladite réglisse est présente à raison de 10% à 30% en poids par rapport au poids total de la composition, de préférence à raison de 15% à 20% en poids par rapport au poids total de la composition.Advantageously, according to the invention, said liquorice is present at a rate of 10% to 30% by weight relative to the total weight of the composition, preferably at a rate of 15% to 20% by weight relative to the total weight of the composition .
Préférentiellement, une composition selon l’invention comprend en outre de la curcumine.Preferably, a composition according to the invention also comprises curcumin.
Avantageusement, selon l’invention, ladite curcumine est présente à raison de 15% à 60% en poids par rapport au poids total de la composition, de préférence à raison de 25X% à 50% en poids par rapport au poids total de la composition.Advantageously, according to the invention, said curcumin is present in an amount of 15% to 60% by weight relative to the total weight of the composition, preferably in an amount of 25X% to 50% by weight relative to the total weight of the composition .
De préférence, une composition selon l’invention comprend en outre au moins un antioxydant choisi dans le groupe constitué du citrate de zinc, de la superoxyde dismutase (SOD), de la N-acétylcystéine, de la vitamine C, de la vitamine E, du D-α-tocophérol, du D-α-tocophéryl acétate, de la choline, du glutathion et leurs mélanges.Preferably, a composition according to the invention also comprises at least one antioxidant chosen from the group consisting of zinc citrate, superoxide dismutase (SOD), N-acetylcysteine, vitamin C, vitamin E, D-α-tocopherol, D-α-tocopheryl acetate, choline, glutathione and mixtures thereof.
De préférence, une composition selon l’invention comprend en outre au moins un excipient pharmaceutiquement acceptable choisi dans le groupe constitué de la cellulose microcristalline, du stéarate de magnésium, du croscarmellose de sodium et leurs mélanges.Preferably, a composition according to the invention also comprises at least one pharmaceutically acceptable excipient chosen from the group consisting of microcrystalline cellulose, magnesium stearate, croscarmellose sodium and mixtures thereof.
Préférentiellement, une composition selon l’invention se présente sous une forme administrable oralement, par exemple sous forme d’un comprimé enrobé ou non, d’une gélule, d’un cachet, d’une poudre soluble, d’une boisson, d’une solution huileuse, d’un comprimé effervescent ou d’une gélule molle.Preferably, a composition according to the invention is in a form that can be administered orally, for example in the form of a coated or uncoated tablet, a capsule, a cachet, a soluble powder, a drink, an oily solution, an effervescent tablet or a soft gelatin capsule.
Avantageusement, une composition selon l’invention se présente sous forme d’un complément alimentaire.Advantageously, a composition according to the invention is in the form of a food supplement.
La présente invention porte également sur une composition suivant l’invention pour utilisation dans le traitement, en particulier pour utilisation dans le traitement préventif, de maladies et/ou de pathologies virales et/ou bactériennes, pour utilisation dans le traitement, en particulier pour utilisation dans le traitement préventif, des inflammations et pour utilisation dans le traitement, en particulier pour utilisation dans le traitement préventif, du syndrome de libération des cytokines (SLC).The present invention also relates to a composition according to the invention for use in the treatment, in particular for use in the preventive treatment, of viral and/or bacterial diseases and/or pathologies, for use in the treatment, in particular for use in the preventive treatment, of inflammations and for use in the treatment, in particular for use in the preventive treatment, of cytokine release syndrome (CLS).
De préférence, une composition selon l’invention est administrée à raison de 1 à 2 prises par jour chez l’adulte.Preferably, a composition according to the invention is administered at the rate of 1 to 2 doses per day in adults.
D’autres caractéristiques, détails et avantages de l’invention ressortiront de l’exemple donné ci-après, à titre non limitatif.Other characteristics, details and advantages of the invention will emerge from the example given below, without limitation.
ExempleExample
Le Tableau 1 ci-dessous est un exemple d’une composition selon l’invention se présentant sous forme d’une gélule.Table 1 below is an example of a composition according to the invention in the form of a capsule.
* AJR = apport journalier recommandé* RDI = recommended daily allowance
** N.D. = non déterminé** N.D. = not determined
La présente invention a été décrite en relation avec des modes de réalisations spécifiques, qui ont une valeur purement illustrative et ne doivent pas être considérés comme limitatifs. D’une manière générale, il apparaîtra évident pour l’homme du métier que la présente invention n’est pas limitée aux exemples illustrés et/ou décrits ci-dessus. L’usage des verbes « comprendre », « inclure », « comporter », ou toute autre variante, ainsi que leurs conjugaisons, ne peut en aucune façon exclure la présence d’éléments autres que ceux mentionnés. L’usage de l’article indéfini « un », « une », ou de l’article défini « le », « la » ou « l’ », pour introduire un élément n’exclut pas la présence d’une pluralité de ces éléments.The present invention has been described in relation to specific embodiments, which are purely illustrative and should not be construed as limiting. In general, it will appear obvious to those skilled in the art that the present invention is not limited to the examples illustrated and/or described above. The use of the verbs "understand", "include", "compose", or any other variant, as well as their conjugations, can in no way exclude the presence of elements other than those mentioned. The use of the indefinite article "un", "une", or of the definite article "le", "la" or "l'", to introduce an element does not exclude the presence of a plurality of these elements.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2004394A FR3109723A1 (en) | 2020-05-04 | 2020-05-04 | Composition for strengthening and / or regulating the immune response |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2004394 | 2020-05-04 | ||
| FR2004394A FR3109723A1 (en) | 2020-05-04 | 2020-05-04 | Composition for strengthening and / or regulating the immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR3109723A1 true FR3109723A1 (en) | 2021-11-05 |
Family
ID=73038016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2004394A Ceased FR3109723A1 (en) | 2020-05-04 | 2020-05-04 | Composition for strengthening and / or regulating the immune response |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR3109723A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001013907A2 (en) * | 1999-08-23 | 2001-03-01 | Immune Balance Technologies Limited Company | Pharmaceutical combination for the treatment of viral infections containing a calcium channel blocker and a quinoline |
-
2020
- 2020-05-04 FR FR2004394A patent/FR3109723A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001013907A2 (en) * | 1999-08-23 | 2001-03-01 | Immune Balance Technologies Limited Company | Pharmaceutical combination for the treatment of viral infections containing a calcium channel blocker and a quinoline |
Non-Patent Citations (4)
| Title |
|---|
| OGA ENOCHE F ET AL: "Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences", EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, EDITIONS MEDECINE ET HYGIENE, CHENE-BOURG, CH, vol. 41, no. 2, 28 August 2015 (2015-08-28), pages 93 - 108, XP035968563, ISSN: 0378-7966, [retrieved on 20150828], DOI: 10.1007/S13318-015-0296-Z * |
| WORKMAN ALAN D. ET AL: "The Role of Quinine-Responsive Taste Receptor Family 2 in Airway Immune Defense and Chronic Rhinosinusitis", FRONTIERS IN IMMUNOLOGY, vol. 9, 28 January 2018 (2018-01-28), CH, XP055780684, ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.00624 * |
| XAVIER CAMILLA ET AL: "Phylogeny of medicinal plants depicts cultural convergence among immigrant groups in New York City", JOURNAL OF HERBAL MEDICINE, vol. 6, no. 1, 1 March 2016 (2016-03-01), pages 1 - 11, XP055780751, ISSN: 2210-8033, DOI: 10.1016/j.hermed.2015.12.002 * |
| YAO LI ET AL: "Quercetin, Inflammation and Immunity", NUTRIENTS, vol. 8, no. 3, 15 March 2016 (2016-03-15), pages 167, XP055466919, DOI: 10.3390/nu8030167 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Erejuwa et al. | Antioxidant protection of Malaysian tualang honey in pancreas of normal and streptozotocin-induced diabetic rats | |
| US5911992A (en) | Method for controlling weight with hypericum perforatum and garcinia cambogia | |
| Kumar et al. | Hesperidin potentiates the neuroprotective effects of diazepam and gabapentin against pentylenetetrazole-induced convulsions in mice: Possible behavioral, biochemical and mitochondrial alterations | |
| Zhao et al. | Protective effects of fucoidan against ethanol-induced liver injury through maintaining mitochondrial function and mitophagy balance in rats | |
| FR2711528A1 (en) | Use of Saccharomyces yeasts for the manufacture of a medicament against cryptosporidiosis. | |
| FR3125409A1 (en) | Food supplement to fight female and male infertility | |
| US20170071963A1 (en) | Hepato-protective beverage composition | |
| KR20230005828A (en) | nutritional health supplements | |
| US20200069758A1 (en) | Composition for use in the preventive and/or curative treatment of non-alcoholic fatty liver disease | |
| FR3109723A1 (en) | Composition for strengthening and / or regulating the immune response | |
| EP0655244B1 (en) | Amino acid composition for the treatment of infections | |
| BE1028259A1 (en) | Composition for strengthening and / or regulating the immune response | |
| FR3058319A1 (en) | COMPOSITION FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSIS | |
| FR3068603A1 (en) | FOOD SUPPLEMENT FOR PROTECTING FEMALE AND MALE FERTILITY | |
| WO2005051370A1 (en) | Composition having liver function protective effect | |
| Laporte et al. | Action de la trypsine et des inhibiteurs trypsiques sur la sécrétion pancréatique | |
| EP1267881B1 (en) | USE OF MnTBAP FOR TREATING HEPATOCELLULAR INSUFFICIENCIES | |
| CA2724937C (en) | Medication for the treatment of gastrointestinal ulcers | |
| BE1024391B1 (en) | Composition for use in the preventive and / or curative treatment of non-alcoholic fatty liver disease | |
| FR2938733A1 (en) | Composition, useful e.g. as dietary supplement and to prevent and/or reduce the damage and/or muscle pain induced by physical activity, comprises L-carnitine and L-cysteine | |
| FR2884691A1 (en) | Oral composition, useful to prepare food complement to aid fertility and to prevent abortion and embryonic malformations, comprises mixture of antioxidizing agents and mixture of energizing elements | |
| BE1026580B1 (en) | Composition for use in the preventive and / or curative treatment of non-alcoholic fatty liver disease | |
| FR3125703A1 (en) | Combination product to help get in shape | |
| BE1026902B1 (en) | MEDICINE AND DIETARY SUPPLEMENT AGAINST GYNECOLOGICAL DISORDERS | |
| WO2004087119A2 (en) | Compositions containing superoxide dismutase and a selected et 5-lipoxygenase inhibitor and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20211105 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| RX | Complete rejection |
Effective date: 20230310 |